Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc....

menu
menu